X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Alfasigma completed acquisition of Jyseleca (filgotinib), which provides European and UK Marketing Authorizations. It is used for the treatment of moderate to severe rheumatoid arthritis.
Lead Product(s): Filgotinib
Therapeutic Area: Immunology Product Name: Jyseleca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alfasigma
Deal Size: $184.9 million Upfront Cash: $54.3 million
Deal Type: Acquisition January 31, 2024
Details:
Under the terms of the agreement, Thermo Fisher will provide GMP manufacturing as well as BioServices and Specialty Logistics for Galapagos’ CAR-T hemato-oncology clinical program, GLPG-5101, being developed for the treatment of Non-Hodgkin’s lymphoma.
Lead Product(s): GLPG-5101
Therapeutic Area: Oncology Product Name: GLPG-5101
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Thermo Fisher Scientific
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2024
Details:
Galapagos and BridGene aim to discover and develop new precision medicines against oncology targets by leveraging Galapagos’ expertise in small molecule drug discovery and translational research along with BridGene’s proprietary IMTAC™ chemoproteomics platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: BridGene Biosciences
Deal Size: $727.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 03, 2024
Details:
The agreement aims to transfer Galapagos’ Jyseleca (filgotinib maleate) business to Alfasigma, marking a significant milestone in its transformation into an innovative biotechnology company with a pipeline aimed for immunology and oncology.
Lead Product(s): Filgotinib
Therapeutic Area: Immunology Product Name: Jyseleca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alfasigma
Deal Size: $229.7 million Upfront Cash: $54.7 million
Deal Type: Agreement January 02, 2024
Details:
GLPG5301 is an autologous, second-generation/4-1BB B-cell maturation antigen (BCMA)-directed CAR-T product candidate which is under phase 1/2 clinical development for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): GLPG5301
Therapeutic Area: Oncology Product Name: GLPG5301
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
Under the terms of the agreement, Landmark Bio will perform GMP manufacturing of clinical trial batches of Galapagos' development programs of chimeric antigen receptor (CAR) T-cell therapies in hematology-oncology in the Boston metropolitan area.
Lead Product(s): CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Landmark Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 06, 2023
Details:
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor and currently in development for the treatment of inflammatory and auto-immune diseases such as systemic lupus erythematosus.
Lead Product(s): GLPG3667
Therapeutic Area: Immunology Product Name: GLPG3667
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
OATD-01, is an oral, once-daily, first-in-class highly selective CHIT1 inhibitor for the treatment of pulmonary sarcoidosis. The inhibition of CHIT1 by OATD‑01 has been shown to reduce inflammation & fibrosis.
Lead Product(s): OATD-01
Therapeutic Area: Immunology Product Name: OATD-01
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Molecure
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor and currently in development for the treatment of inflammatory and auto-immune diseases such as dermatomyositis.
Lead Product(s): GLPG3667
Therapeutic Area: Immunology Product Name: GLPG3667
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Jyseleca (filgotinib) inhibits the action of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of active axial spondyloarthritis and some other conditions.
Lead Product(s): Filgotinib
Therapeutic Area: Immunology Product Name: Jyseleca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
